Stephanie Nahas, AHS 2021: Results from the CaMEO Study

We had the great pleasure of meeting with Stephanie Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss the CaMEO results, a web-based survey to characterize self-reported use of preventive medications for migraine and treatment gaps.

The abstract ‘Characterizing preventive treatment gaps in migraine: Results from the CaMEO study’ & ‘Optimal acute treatment is associated with productivity gains in people with migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.

Questions:

1. Could you give us a brief overview of the CaMEO study and its objectives? (0:22)
2. What did the study reveal about the use of migraine preventative drugs among eligible patients? (1:12)
3. What were the reasons for drug discontinuation? (1:50)
4. What other treatment gaps were identified? (2:39)

Disclosures: Stephanie Nahas has been on the advisory board for Allergen/AbbVie, Zosano, Nesos Corp (formerly Vorso Corp); speaker for Allergan/AbbVie, Amgen/Novartis, Biohaven, Eli Lilly, Impel, Nesos Corp (formerly Vorso Corp), and has received clinical trial principal investigator support for Teva. Stephanie Nahas is also on the editorial board for Springer (Current Pain and Headache Reports), Wolters-Kluwer (UpToDate), and Neurology Learning Network.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.